Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
Glucagon-like peptide-1 receptor agonists
Oral semaglutide
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
01
12
2021
accepted:
24
12
2021
pubmed:
20
1
2022
medline:
20
1
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management.
Identifiants
pubmed: 35044569
doi: 10.1007/s13300-021-01201-z
pii: 10.1007/s13300-021-01201-z
pmc: PMC8767360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
225-240Informations de copyright
© 2022. The Author(s).
Références
International Diabetes Federation (IDF). IDF diabetes atlas. Ninth edition 2019. 2019. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf . Accessed 28 July 2021.
Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.
pubmed: 20609967
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
pubmed: 26249018
pmcid: 4528846
NHS Digital. National Diabetes Audit (NDA) 2020–2021 quarterly report for England, Clinical Commissioning Groups and GP practices—PROVISIONAL. 2021. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/care-processes-and-treatment-targets-3rd-quarter-january-december-2020-data-release . Accessed 14 Sep 2021.
DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19(10):1353–62.
pubmed: 28432726
pmcid: 5643008
DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Prim. 2015;1:15019.
pubmed: 27189025
Mardetko N, Nabergoj Makovec U, Locatelli I, Janez A, Kos M. Uptake of new antidiabetic medicines in 11 European countries. BMC Endocr Disord. 2021;21(1):127.
pubmed: 34172020
pmcid: 8235847
Matza LS, Curtis SE, Jordan JB, Adetunji O, Martin SA, Boye KS. Physician perceptions of GLP-1 receptor agonists in the UK. Curr Med Res Opin. 2016;32(5):857–64.
pubmed: 26807507
Royal College of General Practitioners (RCGP). RCGP Guidance on workload prioritisation during COVID-19. 2020. https://www.rcgp.org.uk/-/media/Files/Policy/A-Z-policy/2020/covid19/RCGP%20guidance/202003233RCGPGuidanceprioritisationroutineworkduringCovidFINAL . Accessed 14 Sep 2021.
Quinn LM, Davies MJ, Hadjiconstantinou M. Virtual consultations and the role of technology during the COVID-19 pandemic for people with type 2 diabetes: the UK perspective. J Med Internet Res. 2020;22(8):e21609.
pubmed: 32716898
pmcid: 7486671
Diabetes UK. Diabetes care during the COVID-19 pandemic; position statement. December 2020. https://diabetes-resources-production.s3.eu-west-1.amazonaws.com/resources-s3/public/2020-12/Position%20statement%20on%20diabetes%20care%20during%20the%20Covid-19%20pandemic.pdf . Accessed 28 Jul 2021.
Aloudah NM, Scott NW, Aljadhey HS, Araujo-Soares V, Alrubeaan KA, Watson MC. Medication adherence among patients with type 2 diabetes: a mixed methods study. PLoS ONE. 2018;13(12):e0207583.
pubmed: 30533042
pmcid: 6289442
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
pubmed: 31186120
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–81.
pubmed: 31530666
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–80.
pubmed: 30903796
pmcid: 6484814
National Institute for Health and Care Excellence (NICE). NICE guideline [NG28] Type 2 diabetes in adults: management. 2015. Updated 2021. https://www.nice.org.uk/guidance/ng28 . Accessed 10 Aug 2021.
Dashora U, Wheatcroft SB, Winocour P, et al. How should we manage people with diabetes in a holistic manner in 2021. Consensus guidance from Cardiology Renal and Metabolic (CaReMe-UK) group. 2021. https://www.guidelinesinpractice.co.uk/diabetes/manage-diabetes-and-comorbidities-with-a-joined-up-strategy/456004.article . Accessed date 23 Aug 2021.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
pubmed: 31497854
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD. Diabetes Care. 2020;43(2):487–93.
pubmed: 31857443
Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020;132(Suppl 2):15–25.
pubmed: 32815436
Wright EE Jr, Aroda VR. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgrad Med. 2020;132(Suppl 2):26–36.
pubmed: 32815423
Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442–51.
pubmed: 31903692
pmcid: 7064975
Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263–77.
pubmed: 32267058
pmcid: 7384149
Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis. Diabetes Ther. 2021;12(5):1325–39.
pubmed: 33723769
pmcid: 8099977
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–32.
pubmed: 31186300
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
pubmed: 31185157
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–27.
pubmed: 31189517
Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–39.
pubmed: 31189520
Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–71.
pubmed: 31530667
pmcid: 7364672
Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020;26:S335–43.
Strain WD, Holst AGSR, Saevereid HA, James MA. Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials. 2020. https://www.easd.org/virtualmeeting/home.html#!resources/effects-of-liraglutide-and-semaglutide-on-stroke-subtypes-in-patients-with-type-2-diabetes-a-post-hoc-analysis-of-the-leader-sustain-6-and-pioneer-6-trials . Accessed date 22 Sep 2021.
Diabetes UK. Survey reveals patients' concerns about diabetes complications. 2009. https://www.diabetes.org.uk/about_us/news_landing_page/survey-reveals-patients-concerns-about-diabetes-complications#:~:text=The%20results%20of%20a%20Diabetes,have%20experienced%20sexual%20dysfunction%3B%20just . Accessed 20 Aug 2021.
ClinicalTrials.gov. NCT03914326. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). 2021. https://clinicaltrials.gov/ct2/show/NCT03914326
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.
pubmed: 33441402
pmcid: 7804890
Wysham CH, Pilon D, Ingham M, et al. Hba1C control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting. Endocr Pract. 2018;24(3):273–88.
pubmed: 29547044
Bain SC, Hansen BB, Malkin SJP, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–77.
pubmed: 31833042
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label. Randomized Clin Trial Diabetes Care. 2018;41(2):258–66.
Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.
pubmed: 28385659
Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–44.
pubmed: 31540867
Capehorn M, Hallén N, Baker-Knight J, Glah D, Hunt B. Evaluating the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for treatment of patients with type 2 diabetes in the UK setting. Diabetes Ther. 2021;12(2):537–55.
pubmed: 33423240
pmcid: 7846640
Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M. Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK. Diabetes Ther. 2020;11(9):2041–55.
pubmed: 32700188
pmcid: 7434815
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
pubmed: 27633186
Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–97.
pubmed: 29178519
pmcid: 5888154
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
pubmed: 31189511
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
pubmed: 27295427
pmcid: 4985288
Bain SC. GLP-1 receptor agonists and diabetic retinopathy. Diabetes Prim Care. 2021;23(4):290.
Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571–80.
pubmed: 29623579
pmcid: 6267549
Miras AD, Pérez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59.
pubmed: 31174993
Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13.
pubmed: 29221659
Brunton SA, Mosenzon O, Wright EE Jr. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020;132(Suppl 2):48–60.
pubmed: 32815453
European Medicines Agency. Rybelsus. Summary of Product Characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf . Accessed 23 Aug 2021.
Aroda VR, Bauer R, Davies AL, et al. 664-P: Incorporating treatment pauses, dosing flexibility, and education to support GLP-1RA therapy persistence. Diabetes. 2021;70(Suppl 1):664-P.
Hauge C, Breitschaft A, Hartoft-Nielsen M, Jensen S, Bækdal T. SAT-140 A drug-drug interaction trial of oral semaglutide with levothyroxine and multiple coadministered tablets. J Endocr Soc. 2019;3:SAT-140.
pmcid: 6552044
Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients’ preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab. 2021;23(2):508–19.
pubmed: 33140575